

South London and Maudsley NHS Foundation Trust: Q3 2016-2017 Performance in Delivering Research

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
	14/LO/2127	168853	A randomized, double-blinded, placebo and lorazepam-controlled, four-way crossover, Phase II study to evaluate the effects of single oral administration of BNC210 on brain activity changes captured by functional magnetic resonance imaging in adults with Generalized Anxiety Disorder	Number Agreed	24	24	Date Agreed	31/03/2016	25	30/06/2016	27	Recruitment Finished	

South London and Maudsley NHS Foundation Trust: Q3 2016-2017 Performance in Delivering Research

			A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnesic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD).	Number Agreed	3	3	Date Agreed	31/05/2017	0	31/10/2016	0	Withdrawn By Sponsor	Recruitment for this study was closed in Oct 2016. We did have a suitable participant, but they decided to not proceed, therefore we have not randomised
--	--	--	---	---------------	---	---	-------------	------------	---	------------	---	----------------------	--